The company has not filed an annual or quarterly report since its Q2 FY2017 10-Q, filed Aug 9, 2017. Its latest SEC filing is a SC 13G/A from Feb 9, 2018.
10-Q for Q2 FY2017, filed Aug 9, 2017
The sections below describe the company as of the FY2016 annual report.
Sells ZADAXIN and other medicines for cancer, infectious diseases and cardiovascular disorders to distributors and hospitals, mainly in China.
10-K for FY2016, filed Mar 9, 2017SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a United States (“U.S.”)-headquartered, China-focused, specialty pharmaceutical company…View ↗
We have two categories of revenues: “product sales revenues” and “promotion services revenues.” Our product sales revenues result from our…View ↗
ZADAXIN is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as an immune system…View ↗
We launched ZADAXIN in China in 1996 and by 2016 our annual worldwide sales of this product reached more than $150 million, 95% of which…View ↗
SciClone sells medicines to importers or distributors, with product revenue tied to delivery. It also earns fees from pharmaceutical partners based on their product sales after designated products are delivered to distributors.
10-K for FY2016, filed Mar 9, 2017Product Revenue. The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN…View ↗
Promotion Services Revenue. The Company recognizes promotion services revenue after designated medical products are delivered to the…View ↗
We have two categories of revenues: “product sales revenues” and “promotion services revenues.” Our product sales revenues result from our…View ↗
$160.1M
10-K for FY2016, filed Mar 9, 2017
$160.1M ↗
Chinese hospitals are reached largely through distributors and sub-distributors, which buy ZADAXIN from licensed importing agents; international sales go through local importers and distributors.
10-K for FY2016, filed Mar 9, 2017
10-K for FY2016, filed Mar 9, 2017
Sinopharm contributed 93%, 97% and 94% of the Company’s total net revenue for the years ended December 31, 2016, 2015 and 2014…View ↗
Yes. It kept 19 cents of every revenue dollar as net income in FY2016.
10-K for FY2016, filed Mar 9, 2017
8-K, filed Oct 13, 2017
On October 13, 2017, pursuant to the terms of the Merger Agreement, Holdco completed its acquisition of the Company through the merger of…View ↗
Held flat. Revenue was $160.1M in FY2016, about the same as the $156.3M of FY2012.
DC Bead entered sales
The older report listed DC Bead among products being registered in China; the latest says SciClone has begun selling it and earning product revenue.
10-K for FY2013, filed Mar 17, 2014 10-K for FY2016, filed Mar 9, 2017We are also pursuing the registration of several other therapeutic products in China. These include: DC Bead®, an embolic-acting bead with…View ↗
We initiated sales and recorded our first product revenue from DC Bead in the third quarter of fiscal 2015. The China Food and Drug…View ↗
Pfizer products shifted roles
The older report included Pfizer products among promotion agreements; the latest describes Pfizer oncology products as product sales and Baxter products as promotion-fee products.
10-K for FY2013, filed Mar 17, 2014 10-K for FY2016, filed Mar 9, 2017We have two categories of revenues: “product sales revenues” and “promotion services revenues.” Our product sales revenues result from our…View ↗
Loading...
